MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Maze Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Maze Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.65B | $197.05M |
| Enterprise Value | $1.28B | $106.56M |
| PB Ratio | 3.64 | 2.14 |
| P/TBV Ratio | 3.64 | 2.46 |
Income (trailing twelve months)
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$145.61M | -$21.44M |
| Net Income | -$133.59M | -$22.46M |
| EBITDA | -$145.61M | -$16.91M |
| EPS (Diluted) | -$2.52 | -$0.83 |
Returns
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -37.3% | -53.1% |
| Return on Assets (ROA) | -32.0% | -41.0% |
| Return on Invested Capital (ROIC) | -292.4% | -32.0% |
| Return on Capital Employed (ROCE) | -28.6% | -37.8% |
Balance sheet
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $411.09M | $62.42M |
| Total Debt | $38.96M | $120.13M |
| Net Cash (Debt) | $372.13M | $15.68M |
| Net Cash Per Share | $6.70 | $0.65 |
| Equity (Book Value) | $453.12M | $48.79M |
| Book Value Per Share | $8.16 | $1.36 |
| Tangible Book Value | $453.12M | $23.06M |
| Working Capital | $397.46M | $75.77M |
Financial position
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 18.31 | 3.30 |
| Quick Ratio | 17.90 | 2.39 |
| Debt / Equity | 0.09 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$106.54M | -$12.35M |
| Capital Expenditures | -$302.00K | -$1.06M |
| Free Cash Flow | -$106.84M | -$20.28M |
| FCF Per Share | -$1.92 | -$0.41 |
Efficiency
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$947.45K | -$732.08K |
| Employee Count | 141 | 73 |
Dividends and yields
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -8.10% | -21.2% |
| FCF Yield | -6.48% | -7.64% |
Shares
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 55,549,200 | 59,128,900 |
| Shares Change (YoY) | 174.6% | 11.1% |
| Shares Change (QoQ) | 11.6% | 0.54% |
| Float | 46,139,700 | 48,744,500 |
| Shares Held by Insiders | 16.9% | 11.8% |
| Shares Held by Institutions | 105.4% | 59.4% |
Scores
| Measure | Maze Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 11.13 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Maze Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.